Category Archives: Biotechnology

Should Biotechnology Stock Viracta Therapeutics Inc (VIRX) Be in Your Portfolio Thursday?  InvestorsObserver

Follow this link:
Should Biotechnology Stock Viracta Therapeutics Inc (VIRX) Be in Your Portfolio Thursday? - InvestorsObserver

Where Does Insmed Incorporated (INSM) Stock Fall in the Biotechnology Field After It Is Lower By -12.23% This Week?  InvestorsObserver

See the article here:
Where Does Insmed Incorporated (INSM) Stock Fall in the Biotechnology Field After It Is Lower By -12.23% This Week? - InvestorsObserver

Where Does Adaptive Biotechnologies Corp (ADPT) Stock Fall in the Biotechnology Field After It Is Up 6.65% This Week?  InvestorsObserver

Read more:
Where Does Adaptive Biotechnologies Corp (ADPT) Stock Fall in the Biotechnology Field After It Is Up 6.65% This Week? - InvestorsObserver

UNITY BIOTECHNOLOGY, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-  Marketscreener.com

View post:
UNITY BIOTECHNOLOGY, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,...

Where Does Travere Therapeutics Inc (TVTX) Stock Fall in the Biotechnology Field After It Is Lower By -14.57% This Week?  InvestorsObserver

Link:
Where Does Travere Therapeutics Inc (TVTX) Stock Fall in the Biotechnology Field After It Is Lower By -14.57% This Week? - InvestorsObserver

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of its first paper describing the CosMx Spatial Molecular Imagers (SMI) chemistry, reproducibility, and sensitivity, as well as the application of the technology to study non-small cell lung cancer and breast cancer samples in Nature Biotechnology.

The paper, entitled High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging, was led by Joseph Beechem, Ph.D., chief scientific officer, NanoString. The team profiled multi-omic data of RNAs and proteins at subcellular resolution using formalin-fixed paraffin-embedded non-small cell lung and breast cancer tissues. Over 18 distinct cell types, 10 unique tumor microenvironments, and 100 pairwise ligand-receptor interactions were discovered.

"CosMx SMI enables researchers to image intact tissue sections at unprecedented levels of cell number, spatial resolution, plex, and multi-analyte," said Dr. Beechem. "This technology allows researchers to discover completely new insights into how tissues function, in health and disease, accelerating the current revolution in spatial biology."

CosMx SMI is the newest product in the company's industry-leading spatial analysis tools portfolio, joining the GeoMx Digital Spatial Profiler (DSP). The GeoMx DSP is a fully-automated spatial profiler with an installed base of more than 300 systems as of June 30, 2022. The GeoMx DSP allows multi-cellular analysis of all the genes in the transcriptome for both human and mouse applications; both platforms are also customizable for other species.

The CosMx SMI compliments GeoMx, extending experiments to single cell and subcellular resolution across the entire tissue section. In addition, both CosMx and GeoMx are compatible with the AtoMx Spatial Informatics Portal (SIP), a cloud-based informatics platform that will provide an integrated ecosystem with streamlined workflows to manage, analyze and share spatial biology data.

The commercial CosMx SMI instruments are expected to ship later this year. In the meantime, researchers can apply the power of SMI to their tissue samples through the SMI Technology Access Program service provided by NanoString. For more information, email smitap@nanostring.com.

To learn more about NanoString's CosMx Spatial Molecular Imager, visit http://www.nanostring.com/CosMx

About NanoString Technologies, Inc.

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx Digital Spatial Profiler, cited in more than 160 peer-reviewed publications, is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics from one FFPE slide. The CosMx Spatial Molecular Imager (SMI) is an FFPE-compatible, single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx Spatial Informatics Platform (SIP) is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. The CosMx SMI and AtoMx SIP platforms are expected to launch in 2022. At the foundation of our research tools is our nCounter Analysis System, cited in more than 6,200 peer-reviewed publications, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. For more information, visit http://www.nanostring.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our products and the anticipated launch of new products and technology. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; the extent and duration of the impact of the COVID-19 pandemic and adverse conditions in the general domestic and global economic markets; the effects of ongoing litigation; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing and product development; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Here is the original post:
Spatial Imaging of 1000 RNAs and 100 Proteins Using the CosMx Spatial Molecular Imager Published in Nature Biotechnology - Business Wire

ReportLinker

Global Biotechnology Kits Market By Kit Type (Purification Kits, Amplification Kits, Detection Kits, Isolation Kits, Others), By Technology (LAMP Technology, PCR, Cell Culture, Sequencing, Chromatography, Electrophoresis, Others), By Parameter Tested (DNA, RNA, Enzymes, Proteins, Others), By Microorganism (Bacteria, Fungi, Virus, Others), By Purpose (On-site v/s Laboratory), By End User (Healthcare, Food & Agriculture, Industrial Processing, Others), By Region, Competition Forecast and Opportunities, 2027

New York, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biotechnology Kits Market - Competition Forecast and Opportunities, 2027" - https://www.reportlinker.com/p06325895/?utm_source=GNW

The global biotechnology kits market is anticipated to observe impressive growth during the forecast period, 2023-2027.The major factors include the increase in inherited diseases and technological advancements.

Biotechnological kits have broad applications such as detecting genetic disorders and various chronic illnesses, and cell culture, which upsurges demand and drives the market growth.Also, multiple advancements are done to increase these kits efficiency and produce new products, which is projected to propel the growth of the biotechnological kits market.

The other factors supporting the markets growth are increasing technological advancements by leading companies, funding of research and development (R&D) projects by governments, and wide application of biotechnological kits in various fields such as pharmaceutical industries, food industries, and agriculture and bioinformatics.Increasing Investments in Biotechnological SectorHeavy investments in the biotechnological sector by the governments and leading biotech companies are expected to boost the growth of the biotechnology kits market globally.With the increasing investments, biotechnological kits are upgraded and made more efficient.

Also, the biotech and pharmaceutical companies expansion is anticipated to significantly increase the biotechnological kits markets growth. Governments have taken initiatives such as the research and developments (R&D) projects which are being funded to build effective and efficient kits which are going to fuel the growth of the market.Increase in Inherited DiseasesNowadays, people are suffering from various genetic disorders, which has propelled the adoption of molecular diagnostics.Key processes of molecular diagnostics such as polymerase chain reaction (PCR) and epigenetics need molecular biotechnological kits.

The rise in population has also increased the demand for biotechnological kits as people are suffering from various inherited and non-inherited diseases.Additionally, the occurrence of the COVID 19 pandemic has also impacted the growth of the biotechnological kits market.

For example, during the outbreak of COVID-19, RT-PCRs were used to detect the viral RNAs in the patients, which resulted in using the purification kits. Also, numerous diagnosis tests were developed to detect COVID-19 and its variant, which augmented the growth of the market.Increase in Technological AdvancementsOver the past few years, immense growth and developments have been witnessed in the biotechnological kits market to make them more accurate, time-saving, and highly sensitive.An increase in technological advancements such as tissue engineering, fermentation, DNA sequencing, and recombinant technology is likely to bolster the growth of the market.

Besides, the advancements, adoption and intersection of the technologies are expected to witness the lucrative growth of the biological kits market.Technological advancements in molecular diagnostic techniques (genome-wide sequencing, droplet digital PCR, and NGS), biotechnological field, cell culture, and growing biomolecular applications are propelling the demand for biotechnological kits.

Thus, in turn, the biotechnological kits market is predicted to grow exponentially in upcoming years. For instance, the launch of the SMART Digest Kit by Thermo Fisher Scientific, Inc., especially aimed at biopharmaceutical applications and proteomic applicationsMarket SegmentationThe global biotechnological kits market is segmented into kit type, technology, parameter tested, microorganism, purpose, end user, company.Based on kit type, the market is divided into purification kits, amplification kits, detection kits, isolation kits, and others.

Based on technology, the market is divided into LAMP technology, PCR, cell culture, sequencing, chromatography, electrophoresis, and others.Based on parameter tested, the market is divided DNA, RNA, enzymes, proteins, and others.

Based on microorganism, the market is divided into bacteria, fungi, virus, and others.Based on purpose, the market is divided into on-site v/s laboratory.

Based on end user, the market is divided into healthcare, food & agriculture, industrial processing, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to establishment of large biotechnological organizations and increasing R&D activities in the country.Market PlayersThermo Fischer Scientific, Inc., QIAGEN N.V., Illumina, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Merck KGaA, Promega Corporation, Takara Bio, Inc, and New England Biolabs UK Limited are some of the leading companies operating in the market.

Report Scope:

In this report, global biotechnological kits market has been segmented into following categories, in addition to the industry trends which have also been detailed below: Biotechnology Kits Market, By Kit Type:o Purification Kitso Amplification Kitso Detection Kitso Isolation Kitso Others Biotechnology Kits Market, By Technology:o LAMP Technologyo PCRo Cell Cultureo Sequencingo Chromatographyo Electrophoresiso Others Biotechnology Kits Market, By Parameter Tested:o DNAo RNAo Enzymeso Proteinso Others

Biotechnology Kits Market, By Microorganism:o Bacteriao Fungio Viruso Others Biotechnology Kits Market, By Purpose:o On-Siteo Laboratory Biotechnology Kits Market, By End User:o Healthcareo Food & Agricultureo Water & Wastewatero Industrial Processingo Others Biotechnology Kits Market, By Region:o North AmericaUnited StatesCanadaMexicoo Asia-PacificChinaIndiaJapanAustraliaSouth Koreao Europe & CISGermanyFranceUnited KingdomSpainItalyo South AmericaBrazilArgentinaColombiao Middle East & AfricaSouth AfricaSaudi ArabiaUAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Biotechnological Kits Market

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).Read the full report: https://www.reportlinker.com/p06325895/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

More:
Global Biotechnology Kits Market - Competition Forecast and Opportunities, 2027 - Yahoo Finance

Breadcrumb Trail Links

Chicago, Illinois(Newsfile Corp. October 12, 2022) MAIA Biotechnology (NYSE: MAIA), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at The Mandarin Oriental Hotel in New York.

This advertisement has not loaded yet, but your article continues below.

Vlad Vitoc will be presenting at 3:00 PM ET on October 26th. Interested parties can register to attend here. Members of the MAIA Biotechnology management will also be holding one-on-one investor meetings throughout the day.

The presentation will also be live-streamed at the following link.

About MAIA Biotechnology

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit http://www.maiabiotech.com.

This advertisement has not loaded yet, but your article continues below.

About The ThinkEquity Conference

The ThinkEquity Conference will gather industry insiders, investors and leading executives from around the world on October 26th in New York. Attendees can expect a full day of company presentations, panel discussions, one-on-one investor meetings and more.

Featured sectors include AI/Big data technology, Biotechnology, EV/EV Infrastructure, Metals & Mining and Oil & Gas.

To register to attend The ThinkEquity Conference, please follow this link.

For further information:Joseph McGuireChief Financial Officer904-228-2603jmcguire@maiabiotech.com

Source: MAIA Biotechnology

#distro

This advertisement has not loaded yet, but your article continues below.

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notificationsyou will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

The rest is here:
MAIA Biotechnology: Invitation to The ThinkEquity Conference - Shoreline Beacon

CRANBURY, N.J. & SHANGHAI--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0682, an orally bioavailable chimeric degrader molecule designed to target ER protein with high potency and selectivity.

The initiation of this study marks the first program from our chimeric degrader portfolio to enter the clinic in China, after the initiation of AC0682 Phase 1 study in the US late last year and the IND clearance by the China National Medical Products Administration (NMPA) earlier this year, said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. Breast cancer is the most common cancer type among Chinese women. We look forward to accelerating the development of AC0682 globally with the goal of bringing transformative medicines to patients worldwide.

The Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0682 treatment in Chinese patients with ER-positive breast cancer. Additional information on this clinical trial can be found on http://www.clinicaltrials.gov (NCT05489679).

About AC0682

AC0682 is an investigational orally bioavailable, chimeric degrader of ER for the potential treatment of ER-positive breast cancers. ER is a hormone-regulated transcription factor that plays a critical role in breast cancer initiation and proliferation, and nearly 80% of breast cancers express ER. In preclinical studies, AC0682 demonstrated potent and selective ER protein degradation with favorable pharmacological properties, as well as promising anti-tumor activity in ER-positive animal tumor models.

About Accutar Biotechnology, Inc.

Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines.

Be transformative. For patients.

To learn more about Accutar, please visit us at http://www.accutarbio.com.

See the original post:
Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer - Business Wire

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) the worlds largest science and public advocacy organization, representing 1,000 members announced today that Rachel King, co-founder and former CEO of GlycoMimetics, Inc., has agreed to serve as interim President and CEO. Kings appointment follows Dr. Michelle McMurry-Heath stepping down as President and CEO to serve as an Advisor to the Executive Committee of the BIO Board of Directors. The organization is searching for a full-time successor.

A long-standing member of the BIO leadership, King brings deep expertise across the industry and previously served as Chair of the BIO Board. King has experience at small and large companies having served as co-founder and former CEO of GlycoMimetics, Inc. and as a senior vice president of Novartis Corporation. Prior to that role she spent more than a decade at Genetic Therapy Inc., including as the companys CEO. She also served at ALZA Corporation and at Bain & Company. She is an expert in the innovation ecosystem as a former Entrepreneur in Residence at New Enterprise Associates, one of the nations leading venture capital firms.

I am deeply committed to the mission and vision of BIO. I look forward to working with BIOs talented staff and its members, said Rachel King, Interim President & CEO. Together, we are going to continue to tackle important policy issues related to health, agriculture, and the environment. Our work advances science and technology and touches people of all backgrounds to improve human health and well-being. The strategy of BIO remains on track.

We are delighted that Rachel King has agreed to take on this interim CEO role as we search for a successor. She is a highly experienced biotech executive who has served in large pharmaceutical organizations as well as an entrepreneur who co-founded her own biotech company. We look forward to working together with Rachel and the staff at BIO to continue important efforts that support innovation for people and patients in all aspects of biotechnology from food and agriculture to healthcare, said Paul Hastings, Chair BIO Executive Committee & Board of Directors.

King will be working closely with the BIO staff to advance innovation that benefits people and patients across BIOs key initiative areas: food and agriculture, industrial and environment, health biotechnology and emerging biotechnology companies.

About the Biotechnology Innovation Association (BIO)BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. For more information about us, please visit http://www.BIO.org and engage with us on Twitter at @IAmBiotech, on LinkedIn, or on YouTube.

Read more:
BIO Announces Appointment of Interim CEO - Business Wire